Lots of interesting abstracts and cases were submitted for TCTAP 2023. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-071
Comparison of Perindopril vs. Losartan With Regard to Pro-Coagulation Factors in Adipocytes Exposed to Sars-Cov-2 Spike Protein
By Hanestya Oky Hermawan, Primasitha Maharany Harsoyo, Makhyan Jibril Al-farabi, I Gde Rurus Suryawan, Meity Ardiana
Presenter
Hanestya Oky Hermawan
Authors
Hanestya Oky Hermawan1, Primasitha Maharany Harsoyo1, Makhyan Jibril Al-farabi2, I Gde Rurus Suryawan3, Meity Ardiana2
Affiliation
General Regional Academic Hospital Dr. Soetomo, Universitas Airlangga, Indonesia1, Airlangga University, Indonesia2, Dr. Soetomo Academic General Hospital, Indonesia3
View Study Report
TCTAP A-071
Basic Science, Animal Models and Preclinical Studies
Comparison of Perindopril vs. Losartan With Regard to Pro-Coagulation Factors in Adipocytes Exposed to Sars-Cov-2 Spike Protein
Hanestya Oky Hermawan1, Primasitha Maharany Harsoyo1, Makhyan Jibril Al-farabi2, I Gde Rurus Suryawan3, Meity Ardiana2
General Regional Academic Hospital Dr. Soetomo, Universitas Airlangga, Indonesia1, Airlangga University, Indonesia2, Dr. Soetomo Academic General Hospital, Indonesia3
Background
Obesity is a strong risk factor for more severe Covid-19 infection as adipocytes play an important role in intermediating the spreading, replication, and release of SARS-COV-2. An increase in pro-coagulation factors (tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1)) was observed in Covid-19 patients with moderate to severe symptoms and is reported to be associated with Angiotensin-converting enzyme 2 (ACE2) overexpression. Cardiovascular medications affecting ACE2, such as Perindopril and Losartan, are hypothesized to have an effect on Covid-19 infection-related coagulopathy. This study aims to identify and compare the effect of perindopril and losartan on TF and PAI-1 levels in adipocytes exposed to SARS-COV-2 spike protein.
Methods
Adipocytes were isolated enzymatically from adipose tissue obtained from an obese male donor. Adipocytes were then exposed to SARS-COV-2 S1 spike protein for 24 hours. After exposure, perindopril and losartan were added to the culture medium. ACE2, TF, and PAI-1expression were measured 2 hours later using ELISA.
Results
SARS-CoV-2 spike protein exposure increased ACE2, TF, and PAI-1 expression. Perindopril addition discernible reduced the tissue factor (TF) expression (4.843 ± 0.396) compared to a positive control (6.857 ± 0.228) (p=0.005) but not losartan(5.624 ± 0.606) (p=0.111). Perindopril was also able to lower PAI-1 expressions (3.484 ± 0.252) compared to a positive control (4.865 ± 0.115) (p=0.001), but the losartan did so more effectively (2.633 ± 0.269) (p=0.000).
Conclusion
Losartan and perindopril both have the ability to lower pro-coagulation factors, proving the value of ACEIs/ARBs in preventing thrombotic complications in Covid-19 patients.